(VIANEWS) – The NYSE opens in less than five hours and Smith & Nephew‘s pre-market value is already 5.13% up.
Smith & Nephew’s last close was $27.86, 22.91% under its 52-week high of $36.14.
The last session, NYSE finished with Smith & Nephew (SNN) jumping 0.69% to $27.86. NYSE slid 0.21% to $15,840.16, after four successive sessions in a row of losses, on what was a somewhat down trend trading session.
About Smith & Nephew
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
Earnings Per Share
As for profitability, Smith & Nephew has a trailing twelve months EPS of $1.02.
PE Ratio
Smith & Nephew has a trailing twelve months price to earnings ratio of 27.21. Meaning, the purchaser of the share is investing $27.21 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.25%.
Moving Average
Smith & Nephew’s value is above its 50-day moving average of $27.82 and higher than its 200-day moving average of $26.88.
More news about Smith & Nephew (SNN).
